Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1

J Acquir Immune Defic Syndr. 2010 Jun;54(2):219-20. doi: 10.1097/QAI.0b013e3181d01d05.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Chemokine CXCL10 / blood*
  • Drug Therapy, Combination
  • Female
  • Genotype
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Hepatitis C / virology
  • Humans
  • Interferon-alpha / therapeutic use
  • Male
  • Predictive Value of Tests
  • Ribavirin / therapeutic use
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Antiviral Agents
  • Chemokine CXCL10
  • Interferon-alpha
  • Ribavirin